Capital Investment Advisors’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
– Sell
-6,002
Closed -$221K – 804
2026
Q1
$221K Buy
6,002
+1,257
+26% +$59.6K ﹤0.01% 690
2025
Q4
$241K Sell
4,745
-162
-3% -$8.28K ﹤0.01% 657
2025
Q3
$272K Sell
4,907
-1,053
-18% -$61.6K ﹤0.01% 620
2025
Q2
$411K Buy
5,960
+152
+3% +$10.3K 0.01% 487
2025
Q1
$403K Buy
5,808
+1,373
+31% +$113K 0.01% 472
2024
Q4
$382K Buy
4,435
+478
+12% +$51.7K 0.01% 468
2024
Q3
$471K Buy
3,957
+49
+1% +$6.54K 0.01% 416
2024
Q2
$558K Buy
3,908
+698
+22% +$92.5K 0.01% 376
2024
Q1
$412K Buy
3,210
+837
+35% +$99.6K 0.01% 428
2023
Q4
$246K Sell
2,373
-65
-3% -$6.43K 0.01% 526
2023
Q3
$222K Buy
+2,438
New +$215K 0.01% 530
2023
Q1
– Sell
-3,866
Closed -$262K – 590
2022
Q4
$262K Buy
+3,866
New +$227K 0.01% 469

Other funds holding NVO

Capital Investment Advisors's NVO Position: Q2 2026 in Review

Capital Investment Advisors sold out of Novo Nordisk (NVO) in Q2 2026, closing a stake of 6,002 shares — an estimated $221K sold.

Capital Investment Advisors first reported a position in NVO in Q4 2022 and held it in 12 quarters. The position peaked at $558K in Q2 2024. 1,356 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Capital Investment Advisors reported no remaining Novo Nordisk position as of Q2 2026 after selling out during the quarter.
  • Capital Investment Advisors sold 6,002 Novo Nordisk shares in Q2 2026, an estimated $221K.
  • Capital Investment Advisors first reported a position in Novo Nordisk in Q4 2022 and held it in 12 quarters.
  • Capital Investment Advisors's Novo Nordisk position peaked at $558K in Q2 2024.
  • 1,356 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Capital Investment Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.